8-K: Arvinas and Pfizer Announce Positive Phase 3 Results for Vepdegestrant in Breast Cancer

Arvinas and Pfizer report positive topline results from the Phase 3 VERITAC-2 trial of vepdegestrant, demonstrating statistically significant improvement in progression-free survival in patients with estrogen receptor 1-mutant advanced or metastatic breast cancer.

Summary

• Arvinas and Pfizer announced positive topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with ER+/HER2advanced or metastatic breast cancer.
• The trial focused on patients whose disease progressed following prior treatment with CDK4/6 inhibitors and endocrine therapy.
• Vepdegestrant is an investigational oral PROTAC ER degrader designed to target and degrade the estrogen receptor.
• The VERITAC-2 trial met its primary endpoint in the ESR1m population, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant.
• The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population.
• The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population.
• Overall survival data was not mature at the time of the analysis, with less than a quarter of the required number of events having occurred.
• The trial will continue to assess overall survival as a key secondary endpoint.
• Vepdegestrant was generally well tolerated, and its safety profile was consistent with previous studies.
• Detailed results will be presented at a medical meeting later in 2025 and shared with global regulatory authorities to potentially support regulatory filings.
• The trial enrolled 624 patients at sites in 26 countries.

Sentiment

Score: 8

Explanation: The document presents positive topline results from a Phase 3 clinical trial, indicating potential for a new treatment option. While overall survival data is not yet mature, the statistically significant improvement in PFS in the ESR1m population is a strong positive signal.

Positives

• Vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the ESR1m population.
• The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population.
• Vepdegestrant was generally well tolerated, with a safety profile consistent with previous studies.
• The FDA granted Fast Track designation for vepdegestrant.

Negatives

• The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population.
• Overall survival data was not mature at the time of the analysis, with less than a quarter of the required number of events having occurred.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the success of the collaboration between Arvinas and Pfizer.
• There are risks associated with clinical development, regulatory approvals, and commercialization of vepdegestrant.
• The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population.
• Overall survival data was not mature at the time of the analysis, with less than a quarter of the required number of events having occurred.

Future Outlook

The companies plan to submit detailed results from VERITAC-2 for presentation at a medical meeting later in 2025 and share the data with global regulatory authorities to potentially support regulatory filings. The trial will continue to assess overall survival as a key secondary endpoint.

Management Comments

• John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas, stated that the data show vepdegestrant has the potential to provide clinically meaningful outcomes for thousands of patients with metastatic breast cancer whose tumors harbor estrogen receptor 1 mutations.
• Megan OMeara, M.D., Interim Chief Development Officer, Pfizer Oncology, said that the data from VERITAC-2 support the potential of vepdegestrant to give patients whose tumors harbor ESR1 mutations additional time without disease progression, compared to fulvestrant.

Industry Context

This announcement is significant as vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial, potentially offering a new treatment option for patients with ER+/HER2metastatic breast cancer who have developed resistance to existing therapies. The results could position Arvinas and Pfizer as leaders in the development of PROTAC-based therapeutics.

Comparison to Industry Standards

• The trial compares vepdegestrant to fulvestrant, a standard endocrine therapy for ER+/HER2breast cancer.
• The results are being compared to a pre-specified target hazard ratio of 0.60 in the ESR1m population.
• Other therapies for ER+/HER2breast cancer include elacestrant, abemaciclib plus fulvestrant, and amcenestrant, as referenced in the document.

Stakeholder Impact

• Positive results could improve treatment options and outcomes for patients with ER+/HER2metastatic breast cancer.
• Successful regulatory filings could lead to increased revenue for Arvinas and Pfizer.
• The results may positively impact investor confidence in Arvinas and Pfizer.

Next Steps

• Detailed results from VERITAC-2 will be submitted for presentation at a medical meeting later in 2025.
• Data will be shared with global regulatory authorities to potentially support regulatory filings.
• The trial will continue to assess overall survival as a key secondary endpoint.

Key Dates